Hu Shanlian: How to normalize and institutionalize drug procurement

On June 23, the fifth batch of national procurement will officially open bids

The normalization and institutionalization of centralized drug procurement in China is an overall plan for reducing drug costs, pushing drug prices back to a reasonable level, and improving drug quality in the future.

Centralized procurement with quantity must be normalized and institutionalized

On June 4, the State Council hosted a medical security work symposium to study and deploy the reform of centralized procurement of medicines and consumables, and proposed to "adhere to the national game of chess, steadily and orderly expand the coverage of centralized procurement, and include more medicines and consumables.

The significance of centralized procurement is that the state organizes centralized procurement of drugs, promotes fair competition in the market, and returns the price of drugs to their true value.

Adhere to the principle of "guarantee basics", include drugs with large amounts and high purchase amounts in the medical insurance drug catalogue into the procurement scope, and produce drugs and consumables from selected companies through fair competition in quality and price.

Summarize the experience of centralized mining

2.

3.

  4.

  5.

  6.

  7.

  8.

  In the future, the country will normalize the centralized procurement of medicines, continue to expand the scope of centralized procurement, and insist on "should be collected as much as possible
.
" Fully implement the centralized procurement requirements for drugs and high-value medical consumables, make it the dominant model, expand the reform effect, and form reasonable, fair, fair, affordable, and reasonable return prices
.
  

  All parts of the country should further explore different ways of drug procurement with volume, such as inter-provincial alliance procurement, provincial-level procurement with volume, and medical group procurement models
.
To encourage hospitals and doctors to ensure the use of bid-winning drugs, in addition to the procurement and use of selected drugs by medical institutions as one of the performance evaluation content, how to ensure medical quality is also a direction worthy of further research
.
  

  It is very important to do a good job in the quality evaluation of drugs and consumables that are collected by volume, and to increase the public's recognition and trust in the consistency evaluation of the quality and efficacy of chemical drugs
.
Recently, Xuanwu Hospital and other 20 medical institutions selected the first batch of 14 selected drugs to carry out real-world research and evaluation of clinical efficacy and safety, involving cardiovascular disease, neuropsychiatry, chronic hepatitis B, tumors, and anesthesia.
For other medicines, more than 110,000 patient samples were observed for medication, and the time span was as long as two years
.
The National Medical Insurance Administration's "Release Conference on the Efficacy and Safety of Real-World Research Results of Selected Drugs in Collective Procurement" confirmed that the selected generic drugs are equivalent to the original drugs in clinical efficacy and use, and there is no statistical difference in adverse reactions
.
These evidence-based medical evidences prove that the selected generic drugs and the original research drugs not only have the same pharmaceutical composition and bioequivalence, but also achieve equivalent clinical treatment effects
.
In the future, the country will normalize the evaluation of the effect of centralized drug procurement, analyze from the two aspects of cost and effect, and explore the introduction of clinical efficacy evaluation and pharmacoeconomic evaluation into centralized procurement
.